Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer

被引:92
作者
Bijelic, L. [1 ]
Jonson, A. [2 ]
Sugarbaker, P. H. [1 ]
机构
[1] Washington Canc Inst, Peritoneal Surface Malignancy Program, Washington, DC 20010 USA
[2] Washington Hosp Ctr, Depy Womens Serv, Washington, DC 20010 USA
关键词
cytoreductive surgery; heat; hyperthermia; intraperitoneal chemotherapy; ovarian cancer;
D O I
10.1093/annonc/mdm137
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this systematic review is to critically evaluate cytoreductive surgery combined with heated intraoperative intraperitoneal chemotherapy in the treatment of ovarian cancer. A systematic review of all manuscripts published in the English literature that met predetermined inclusion criteria was carried out. Data concerning cytoreductive surgery, method and agents for administration of heated intraoperative intraperitoneal chemotherapy, morbidity, mortality, hospital stay and survival were extracted, critically reviewed and tabulated. Fourteen studies were analyzed. A wide variety of drug doses, methods of intraperitoneal chemotherapy administration and volume of chemotherapy solution were used. Seven studies showed that patients with complete cytoreduction had the greatest benefit. The median overall survival for primary and recurrent disease ranged from 22 to 54 months and the median disease-free survival from 10 to 26 months. The rates of significant morbidity associated with this combined treatment were low, ranging from 5% to 36%. The median mortality was 3% (range 0%-10%). Cytoreductive surgery combined with heated intraoperative intraperitoneal chemotherapy is a treatment option for patients with ovarian cancer that is worthy of further investigation. Selection criteria for patients most likely to benefit need to be defined.
引用
收藏
页码:1943 / 1950
页数:8
相关论文
共 45 条
[1]   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[2]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[3]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[4]  
Chatzigeorgiou K, 2003, Zentralbl Gynakol, V125, P424
[5]  
de Bree E, 2003, ANTICANCER RES, V23, P3019
[6]  
EISENKOP SM, 1995, CANCER, V76, P1606, DOI 10.1002/1097-0142(19951101)76:9<1606::AID-CNCR2820760917>3.0.CO
[7]  
2-H
[8]  
Eisenkop SM, 2000, CANCER, V88, P144, DOI 10.1002/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO
[9]  
2-X
[10]  
Flessner MF, 2001, J AM SOC NEPHROL, V12, P807, DOI 10.1681/ASN.V124807